Zhejiang-based bio-pharmaceutical manufacturer selling drugs and health products in China.
Zhejiang-based bio-pharmaceutical manufacturer selling drugs and health products in China.
Moat: none
Headquarters: Zhejiang, China · Employees: 1,808
Size Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.67B, the 1369th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥21.24 on 18 Nov 2026.
Performance Over six months the shares fell 11.9%, against -3.0% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 20 in its peer set.
Growth Revenue grew 6.8% over the last twelve months (peer median +13.8%); the operating margin is 38.8% (peer median 12.0%).
Valuation It trades at 26.3× forward earnings against a peer median of 22.0× (8th most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is +8 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 8.9 points above its cost of capital (11.4% WACC).
Next results Next results expected around 16 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.12B | CN¥1.06B | CN¥922M | CN¥845M | CN¥893M |
| Revenue growth | — | +15% | +9% | -5% | — |
| Gross profit | CN¥1.07B | CN¥960M | CN¥834M | CN¥772M | CN¥827M |
| EBITDA | n/a | CN¥456M | CN¥368M | CN¥345M | CN¥367M |
| Net income | CN¥427M | CN¥381M | CN¥318M | CN¥310M | CN¥349M |
| Free cash flow | CN¥448M | CN¥307M | CN¥147M | CN¥179M | CN¥180M |
| Capital expenditure | CN¥41.4M | CN¥119M | CN¥118M | CN¥209M | CN¥189M |
| Total debt | CN¥12.1M | CN¥18.4M | CN¥25.6M | CN¥62.4M | CN¥16.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300357.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +10.3% | -3.2% | 3rd highest of 21 |
| 6-month return | -11.9% | -3.0% | 9th lowest of 20 |
| Distance from 52-week high | -37.2% | -32.1% | 8th lowest of 21 |
| Revenue growth (TTM) | +6.8% | +13.8% | 10th lowest of 20 |
| Operating margin | 38.8% | 12.0% | highest of 20 |
| Forward P/E | 26.3× | 22.0× | 8th most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 18.4% | 12.8% | 8th most demanding of 16 |
| Growth delivered (Del g) | +10.8% | +6.8% | 6th highest of 16 |
| Hurdle (Req g minus delivered) | +7.6 pp | +8.6 pp | 8th least demanding of 16 |
| ROIC minus cost of capital | +8.9 pp | -2.7 pp | 5th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.67B | -12% | +7% | 39% | 26.3× | 18.4% | +10.8% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| Indegene INDGN.NS | India | $1.69B | +28% | +36% | 12% | 29.5× | 31.4% | +29.4% |
| Mayinglong Pharmaceutical 600993.SS | China | $1.70B | +2% | +7% | 17% | 17.0× | -3.5% | +6.8% |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +8% | +15% | 35% | 9.2× | -14.9% | +13.5% |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.70B | +2% | +17% | 31% | 21.4× | 24.3% | +15.7% |
| ApicHope Pharmaceutical 300723.SZ | China | $1.70B | -36% | -28% | -50% | 22.0× | 11.3% | -11.0% |
| Faes Farma FAE.MC | Spain | $1.71B | +6% | +32% | 14% | 17.4× | 3.7% | +9.9% |
| Maze Therapeutics MAZE | United States | $1.71B | +27% | -100% | -821% | n/a | n/a | n/a |
| BrightGene Bio-Medical Technology 688166.SS | China | $1.71B | -57% | +14% | 7% | 74.9× | 35.3% | +9.2% |
| NATCO Pharma NATCOPHARM.NS | India | $1.73B | -27% | -30% | 17% | 19.1× | 20.5% | +19.0% |
| Tonghua Golden-Horse Pharmaceutical Industry 000766.SZ | China | $1.62B | -47% | -18% | 9% | n/a | 33.0% | +0.9% |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.62B | -30% | +30% | 10% | n/a | 42.4% | +23.0% |
| Anupam Rasayan India ANURAS.NS | India | $1.61B | -3% | +24% | 16% | 49.9× | n/a | n/a |
| Sino Biological 301047.SZ | China | $1.60B | +27% | +20% | 17% | 51.6× | 31.1% | -15.1% |
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.60B | -31% | -13% | 12% | 57.4× | 12.8% | -14.0% |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.59B | -14% | -13% | 6% | 12.6× | -6.6% | -5.6% |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.59B | -8% | +18% | 7% | 29.0× | n/a | n/a |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.59B | 0% | -4% | 15% | 47.2× | 6.0% | -4.3% |
| Agios Pharmaceuticals AGIO | United States | $1.78B | +4% | +214% | -298% | n/a | n/a | n/a |
| Shenzhen Hepalink Pharmaceutical 9989.HK | Hong Kong | $1.78B | -13% | -1% | 8% | 8.7× | -0.4% | -0.2% |